Archive for the ‘Hormone therapy’ Category

URO TODAY: Eighteen heterosexual US couples have taken part in a survey to find out how their sex lives are affected when the man is undergoing testosterone-reducing hormone treatment for prostate cancer. READ MORE>

The finding that some couples are able to enjoy satisfying sex, despite castrate levels of testosterone, raised questions about how patients are prepared to undergo hormone therapy and how they are managed.

Read Full Post »

URO TODAY: Hormone treatment for prostate cancer slightly raises the risk of heart problems – but not enough to discredit hormone therapy as an effective option, according to a study of 76,000 men by UK and Swedish scientists. READ MORE>

Read Full Post »

URO TODAY:  Stopping the enzyme process that allows a prostate tumour to produce androgens could be the key in halting a tumour’s growth, researchers in Texas say. READ MORE>

Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens.

Read Full Post »

URO TODAY: Of all cancers, prostate cancer is the most sensitive to hormones: it is thus very important to take advantage of this unique property and to always use optimal androgen blockade when hormone therapy is the appropriate treatment.  READ MORE>

Read Full Post »

URO TODAY: Acupuncture may stop hot flashes during hormone therapy for prostate cancer, according to early results in a small US trial. READ MORE>

Read Full Post »

AFP: A combination of radiation therapy and hormone treatment can cut by 43 percent the risk of death in men suffering from locally advanced or high-risk prostate cancer, according to research presented at the annual American Society of Clinical Oncology conference. READ MORE>

It showed that adding radiation therapy to androgen deprivation therapy produced significant benefits for the cancer patients.

Read Full Post »

URO TODAY: The recovery of testosterone after long-term androgen deprivation therapy for prostate cancer is slow, according to a study of about 20 patients who had been receiving hormone drugs for a mean seven years. READ MORE>

Read Full Post »

URO TODAY:  Abiraterone acetate is a promising treatment for advanced prostate cancer patients and is being tested in a Phase III trial for men with progressive castration-resistant prostate cancer who have  not had chemotherapy.

A Phase III trial for patients following prior chemotherapy has been completed and is awaiting analysis. READ MORE>

Read Full Post »

URO TODAY:  The five main prostate cancer treatments can all have bad side effects, so a panel of 15 specialists have compared them and come up with some recommended improvements.

Prostate cancer (PC) is one of the tumours with the highest incidence in recent years. PC therapies have several adverse effects.

A panel consensus recommendation has been made to prevent or ameliorate complications in PC treatment to improve quality of life.

Fifteen specialists have met to analyse the different toxicities associated with PC treatment.

Each medical specialist searched National Library of Medicine PubMed citations about these secondary effects and his specialty from 1999 to 2009 to propose measures for their prevention/amelioration.

  • Surgery is associated with incontinence and impotence.
  • Radiotherapy can produce acute, late urological and gastrointestinal toxicity.
  • Brachytherapy can produce acute urinary retention.
  • Chemotherapy is associated with haematotoxicity. peripheral neuropathy and diarrhoea.
  • And hormone therapy can produce osteoporosis, metabolic syndrome, cognitive and muscular alterations, cardiotoxicity, etc.

Improvement in surgical techniques and technology (IMRT/IGRT) can prevent surgical and radiotherapeutic toxicity, respectively.

Brachytherapy toxicity can be prevented with precise techniques to preserve the urethra.

Chemotherapy toxicity can be prevented with personalized schedules of treatment and close follow-up of iatrogenia

And hormone therapy toxicity can be prevented with close follow-up of possible secondary effects.

Read Full Post »

NEW PROSTATE CANCER INFO-LINK: A new study has shown that the generically available, oral, bisphosphonate risedronate (Actonel) can prevent bone loss and related effects in patients receiving hormonal therapy for prostate cancer. READ MORE>

Read Full Post »

Older Posts »